

Alzheimer's Disease (AD)

A Study to Evaluate the Efficacy and Safety of RO7105705 in Patients With Prodromal to Mild Alzheimer's Disease

Trial Status
Terminated

Trial Runs In
13 Countries

Trial Identifier
NCT03289143 2017-001800-31
GN39763

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This was a phase II, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of Semorinemab in participants with prodromal to mild Alzheimer's disease. An optional 96-week open-label extension period was available to participants who completed the double-blind treatment period and who, in the judgment of the investigator, would potentially benefit from open-label Semorinemab treatment.

Genentech, Inc.
Sponsor

Phase 2
Phase

NCT03289143 2017-001800-31 GN39763
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥ 50 Years & ≤ 80 Years

Healthy Volunteers
No